- Home
- Programs and Groups
- Shared Resources
- Faculty
- Clinical Trials
- Tumor Registry
- Education
- About DCI
Quick Links
Adult Clinical Trials - Brain Cancer
If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact 919-684-5301 or visit The Preston Robert Tisch Brain Tumor Center at Duke.
Items 1 - 20 of 20
Items 1 - 20 of 20
Primary and Recurrent Glioma Registry (PRoGREss)
Principal Investigator: Annick Desjardins
Phase: N/A
Phone: 919-684-5301
Principal Investigator: Annick Desjardins
Phase: N/A
Phone: 919-684-5301
A Pilot Safety Study of the Administration of Bone Marrow Derived Stem Cells (ALD-451) in WHO grade IV Malignant Glioma
Principal Investigator: Annick Desjardins
Phase: Phase I
Phone: 919-684-5301
Principal Investigator: Annick Desjardins
Phase: Phase I
Phone: 919-684-5301
Dose-finding and Safety Study of PVSRIPO Against Recurrent Glioblastoma
Principal Investigator: Annick Desjardins
Phase: Phase I
Phone: 919-684-5301
Principal Investigator: Annick Desjardins
Phase: Phase I
Phone: 919-684-5301
CDX110-06: A Phase II Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma (The ReACT Study)
Principal Investigator: Annick Desjardins
Phase: Phase II
Phone: 919-684-5301
Principal Investigator: Annick Desjardins
Phase: Phase II
Phone: 919-684-5301
Phase 1b/2a Study Combining LY2157299 with Standard Temozolomide-based Radiochemotherapy in Patients with Newly Diagnosed Malignant Glioma
Principal Investigator: Annick Desjardins
Phase: Phase II
Phone: 919-684-5301
Principal Investigator: Annick Desjardins
Phase: Phase II
Phone: 919-684-5301
Phase II Trial of Bevacizumab, Radiation Therapy and Temodar followed by Bevacizumab and Temodar with Continuation of Bevacizumab Beyond Progression (BBP-Bevacizumab Beyond Progression)
Principal Investigator: Annick Desjardins
Phase: Phase II
Phone: 919-684-5301
Principal Investigator: Annick Desjardins
Phase: Phase II
Phone: 919-684-5301
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma (The ACT IV Study)
Principal Investigator: Annick Desjardins
Phase: Phase III
Phone: 919-684-5301
Principal Investigator: Annick Desjardins
Phase: Phase III
Phone: 919-684-5301
PBTC-N11: Immunologic Profile of Patients with Newly Diagnosed Medulloblastoma at Initial Diagnosis and During Standard Radiation and Chemotherapy
Principal Investigator: Sridharan Gururangan
Phase: N/A
Phone: 919-668-5364
Principal Investigator: Sridharan Gururangan
Phase: N/A
Phone: 919-668-5364
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults with Recurrent or Refractory Medulloblastoma
Principal Investigator: Sridharan Gururangan
Phase: Phase II
Phone: 919-668-5364
Principal Investigator: Sridharan Gururangan
Phase: Phase II
Phone: 919-668-5364
Multicenter, Phase II Assessment of Tumor Hypoxia in Glioblastoma Using 18F-Fluoromisonidazole (FMISO) With PET and MRI
Principal Investigator: Jenny Hoang
Phase: Phase II
Phone: 919-684-7807
Principal Investigator: Jenny Hoang
Phase: Phase II
Phone: 919-684-7807
Determination of the Optimal PTV for Brain Metastases Treated with Novalis Tx Stereotactic Radiosurgery
Principal Investigator: John Kirkpatrick
Phase: N/A
Phone: 919-668-3726
Principal Investigator: John Kirkpatrick
Phase: N/A
Phone: 919-668-3726
ACNS0332 Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Principal Investigator: Susan Kreissman
Phase: Phase III
Phone: 919-684-3401
Principal Investigator: Susan Kreissman
Phase: Phase III
Phone: 919-684-3401
Recurrent GBM Stem Cell Tumor Amplified RNA Immunotherapy Trial
Principal Investigator: Duane Mitchell
Phase: Phase I
Phone: (919) 684-5301
Principal Investigator: Duane Mitchell
Phase: Phase I
Phone: (919) 684-5301
Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive T Cell Therapy during Recovery from Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation
Principal Investigator: Duane Mitchell
Phase: Phase I
Phone: 919-668-5364
Principal Investigator: Duane Mitchell
Phase: Phase I
Phone: 919-668-5364
Clinical and Neurocognitive Outcomes in Long-term Survivors of Primary Glioblastoma Multiforme
Principal Investigator: Katherine Peters
Phase: N/A
Phone: 919-684-5301
Principal Investigator: Katherine Peters
Phase: N/A
Phone: 919-684-5301
Effects of Low-Dose Naltrexone on Quality of Life in High-Grade Glioma Patients: A Placebo-Controlled, Double-Blind Randomized Trial
Principal Investigator: Katherine Peters
Phase: N/A
Phone: 919-684-5301
Principal Investigator: Katherine Peters
Phase: N/A
Phone: 919-684-5301
Functional and Neurocognitive Profile of Patients Receiving Bevacizumab Containing Treatment Regimens for Glioblastoma Multiforme
Principal Investigator: Katherine Peters
Phase: N/A
Phone: 919-684-5301
Principal Investigator: Katherine Peters
Phase: N/A
Phone: 919-684-5301
A Phase I/II Single-Arm Open-Label Multicenter Study of VB-111 in Patients with Recurrent Glioblastoma Multiforme (VB-111-122)
Principal Investigator: Katherine Peters
Phase: Phase II
Phone: 919-684-5301
Principal Investigator: Katherine Peters
Phase: Phase II
Phone: 919-684-5301
Phase II Study to Evaluate the Efficacy and Safety of AMG 102 and Avastin in Subjects with Recurrent Malignant Glioma
Principal Investigator: Katherine Peters
Phase: Phase II
Phone: (919) 684-5301
Principal Investigator: Katherine Peters
Phase: Phase II
Phone: (919) 684-5301
Phase II single-arm study of pre-operative stereotactic radiosurgery for brain metastases.
Principal Investigator: John Sampson
Phase: Phase II
Phone: (919) 684-5301
Principal Investigator: John Sampson
Phase: Phase II
Phone: (919) 684-5301
